Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: BIOLOGICAL: adagloxad simolenin combined with OBI-821|DEVICE: Globo H IHC Assay|OTHER: Standard of care treatment
Sponsor: OBI Pharma, Inc